Precigen

Precigen, headquartered in Germantown, Maryland, operates as a discovery and clinical-stage biopharmaceutical company. It targets diseases in immuno-oncology, autoimmune disorders, and infectious diseases using advanced gene and cell therapy technologies. The company employs non-viral and viral expression systems, along with genome, DNA, RNA, and protein engineering to develop precision bioengineering switch technologies for controlling gene expression and regulation. Precigen’s UltraCAR-T platform is a CAR-T cell therapy that utilizes non-viral multi-gene delivery and overnight manufacturing, significantly reducing the manufacturing and treatment time for autologous CAR-T to just one day. UltraCAR-T cells, produced using the non-viral Sleeping Beauty system, express antigen-specific CAR, kill switch, and mbIL15 genes. The company also develops AdenoVerse, a gene therapy platform using proprietary adenovectors with a large genetic payload capacity and low seroprevalence in humans, engineered to be replication deficient in vivo. Another platform, ActoBiotics, uses genetically modified Lactococcus lactis to deliver therapeutic agents either orally or topically, manufactured through a scalable cGMP process. Additionally, Precigen focuses on multifunctional therapeutics that target multiple pathways to enhance T cell activation and employs the RheoSwitch Therapeutic System for precise gene expression control. The company also utilizes the UltraVector platform for advanced DNA construction and gene expression programs. Precigen supports continued research through a postdoctoral program offering grants and operates subsidiaries including Precigen ActoBio and Precigen Exemplar.